Compare BOC & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BOC | ACRS |
|---|---|---|
| Founded | 2009 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 377.5M | 311.0M |
| IPO Year | 2010 | 2015 |
| Metric | BOC | ACRS |
|---|---|---|
| Price | $12.11 | $4.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $10.20 |
| AVG Volume (30 Days) | 139.3K | ★ 1.4M |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.01 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $114,376,348.00 | $1,683,000.00 |
| Revenue This Year | $5.79 | N/A |
| Revenue Next Year | $4.76 | $4.24 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.64 | N/A |
| 52 Week Low | $11.03 | $1.20 |
| 52 Week High | $15.60 | $4.89 |
| Indicator | BOC | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 43.21 | 61.28 |
| Support Level | $11.88 | $3.16 |
| Resistance Level | $12.61 | $4.56 |
| Average True Range (ATR) | 0.26 | 0.23 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 14.29 | 82.93 |
Boston Omaha Corp is a diversified holding company engaged in outdoor billboard advertising, broadband services, surety insurance, and related brokerage activities, and asset management. The company generates revenue mainly from leasing advertising space on billboards, providing broadband internet services, and earning premiums and commissions from its insurance operations. In addition, it holds minority equity investments in various businesses, including real estate-related and other industries.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.